New York, March 30, 2026 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) celebrates today’s announcement that the U.S. Food and Drug Administration (FDA) has approved a High Dose Regimen ...

Please provide your email address to receive an email when new articles are posted on . Topline data from an ongoing clinical trial of a higher dose regimen of Spinraza in treatment-naive, symptomatic ...

Spinraza is approved in more than 71 countries to treat infants, children, and adults with spinal muscular atrophy. The study achieved a statistically significant improvement in motor function in ...

A trial of Biogen’s spinal muscular atrophy (SMA) therapy Spinraza (nusinersen) suggests that a higher dose provides benefits to a broad range of patients—including those who have and have not been ...

(RTTNews) - Biogen Inc. (BIIB) announced that the European Commission has granted marketing authorisation for a high-dose regimen of SPINRAZA, comprised of 50 mg/5 mL and 28 mg/5 mL doses, for 5q ...

The new data show that an axonal injury and neurodegeneration biomarker was reduced in nearly all study participants treated with Spinraza. The evaluates clinical outcomes and safety following ...

The approval was anchored on data from the pivotal DEVOTE study that investigated the efficacy and safety of the High Dose Regimen of SPINRAZA in treatment-naïve and previously treated SPINRAZA ...

MEDICINES for babies with spinal muscular atrophy will be funded by the NHS for all patients for the first time. Little Mix ...

Spinraza is a medication used in children (including newborns) and adults to treat spinal muscular atrophy. Treatment begins with four loading doses, followed by one maintenance dose every 4 months.